StockData

Immunocore vs Vir Biotechnology

IMCR and VIR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMCR and VIR compare

Immunocore and Vir Biotechnology are about the same size, with market caps of $1.5B and $1.6B.

Vir Biotechnology grew revenue faster over the last twelve months (1496% versus 21.0% for Immunocore).

Immunocore keeps more of each dollar of sales as profit, with a net margin of −4.2% compared with −83.0% at Vir Biotechnology.

Vir Biotechnology scores higher on the StockData Score (11 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMCRVIR
Size and price
Market cap$1.5B$1.6B
Share price$28.88$9.58
Change, 1 year−18.3%75.1%
Change, 5 years−20.6%−73.4%
Beta (5Y)0.140.75
Employees524367
StockData Score
Total score711 (better)
Valuation score13 (better)
Growth score2 (better)1
Performance score3 (better)2
Health score15 (better)
Dividend score00
Valuation
P/S3.5× (better)5.3×
P/B3.5×1.6× (better)
FCF yield−2.8% (better)−12.6%
Fair value$32.90$13.35
Margin of safety12.2%28.2% (better)
Growth
Revenue growth (TTM)21.0%1496% (better)
Revenue growth, 5Y average–−2.1%
Profitability
Gross margin98.9%–
Operating margin−5.2% (better)−92.4%
Net margin−4.2% (better)−83.0%
FCF margin−9.6% (better)−67.1%
Return on equity−4.5% (better)−26.1%
Return on invested capital–−55.2%
Financial health
Debt / equity–0.00
Interest coverage−1.8×–
Current ratio4.476.04 (better)
Altman Z-score1.442.72 (better)
Piotroski F-score33
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%86.6%
Held by insiders15.5%17.0%
Insider net buying, 12 months−$1.9M (better)−$4.0M
Short interest, % of float–12.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.